AP433A - Endothelin receptor antagonistis. - Google Patents

Endothelin receptor antagonistis. Download PDF

Info

Publication number
AP433A
AP433A APAP/P/1992/000440A AP9200440A AP433A AP 433 A AP433 A AP 433A AP 9200440 A AP9200440 A AP 9200440A AP 433 A AP433 A AP 433A
Authority
AP
ARIPO
Prior art keywords
irs
indane
hydrogen
methoxyphenyl
methylenedioxyphenyl
Prior art date
Application number
APAP/P/1992/000440A
Other languages
English (en)
Other versions
AP9200440A0 (en
Inventor
Russell Donovan Cousins
John Duncan Elliott
Maria Amparo Lago
Jack Dale Leber
Cathrine Elizabeth Peishoff
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AP9200440A0 publication Critical patent/AP9200440A0/xx
Application granted granted Critical
Publication of AP433A publication Critical patent/AP433A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/1992/000440A 1991-11-05 1992-11-04 Endothelin receptor antagonistis. AP433A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78787091A 1991-11-05 1991-11-05
US85419592A 1992-03-20 1992-03-20

Publications (2)

Publication Number Publication Date
AP9200440A0 AP9200440A0 (en) 1993-01-31
AP433A true AP433A (en) 1995-11-17

Family

ID=27120702

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000440A AP433A (en) 1991-11-05 1992-11-04 Endothelin receptor antagonistis.

Country Status (32)

Country Link
EP (1) EP0612244B1 (pt)
JP (1) JP2667294B2 (pt)
KR (1) KR100342960B1 (pt)
CN (2) CN1034569C (pt)
AP (1) AP433A (pt)
AT (1) ATE205711T1 (pt)
AU (1) AU669866B2 (pt)
BG (1) BG61523B1 (pt)
BR (1) BR9206722A (pt)
CA (1) CA2122820A1 (pt)
CZ (1) CZ287406B6 (pt)
DE (1) DE69232072T2 (pt)
DK (1) DK0612244T3 (pt)
ES (1) ES2164054T3 (pt)
FI (1) FI942059A7 (pt)
HU (1) HUT67665A (pt)
IL (1) IL103621A0 (pt)
MA (1) MA22758A1 (pt)
MX (1) MX9206348A (pt)
MY (1) MY108579A (pt)
NO (1) NO304887B1 (pt)
NZ (1) NZ245000A (pt)
OA (1) OA09921A (pt)
PL (1) PL176250B1 (pt)
PT (1) PT101038B (pt)
RO (1) RO117847B1 (pt)
RU (1) RU2125980C1 (pt)
SI (1) SI9200297B (pt)
SK (1) SK282098B6 (pt)
TW (1) TW298590B (pt)
UA (1) UA44686C2 (pt)
WO (1) WO1993008799A1 (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5817693A (en) 1991-11-05 1998-10-06 Cousins; Russell Donovan Endothelin receptor antagonists
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
WO1993023404A1 (en) * 1992-05-19 1993-11-25 Immunopharmaceutics, Inc. Compounds that modulate endothelin activity
ES2062927B1 (es) * 1992-12-17 1995-07-01 Smithkline Beecham Corp Antagonistas de los receptores de endotelina y procedimiento para su preparacion.
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
GB9307694D0 (en) 1993-04-14 1993-06-02 Smithkine Beecham Corp Novel compounds
FI941826A7 (fi) * 1993-04-21 1994-10-22 Takeda Chemical Industries Ltd Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
SK130595A3 (en) * 1993-04-27 1996-06-05 Smithkline Beecham Corp New indane and indene derivatives, preparing method, pharmaceutical compositions containing them and their use
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
WO1995004530A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995004534A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995005374A1 (en) * 1993-08-18 1995-02-23 Banyu Pharmaceutical Co., Ltd. Fused heteroaromatic cyclopentene derivative having endothelin-antagonist activity
US5714479A (en) * 1993-08-18 1998-02-03 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
WO1995012611A1 (en) * 1993-11-01 1995-05-11 Japat Ltd. Endothelin receptor antagonists
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
WO1995033748A1 (en) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
WO1995035107A1 (en) * 1994-06-20 1995-12-28 Smithkline Beecham Corporation Endothelin receptor antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
CA2517691A1 (en) * 1994-08-19 1996-02-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
EP0799225A4 (en) * 1994-12-23 1998-03-25 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5599811A (en) * 1995-02-21 1997-02-04 Warner-Lambert Company Benzothiazine dioxides as endothelin antagonists
ATE186054T1 (de) * 1995-06-30 1999-11-15 Cerbios Pharma Sa Glykoside, deren zuckerfreie abbauprodukte und derivate derselben
DE19527568A1 (de) * 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
ATE227726T1 (de) * 1995-08-17 2002-11-15 Takeda Chemical Industries Ltd Thienopyrimidinderivate als endothelin antagonisten
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
EP0915699A4 (en) * 1995-11-08 2008-06-25 Smithkline Beecham Corp STEREPSELECTIVE SYNTHESIS OF ENDOTHELIN RECEPTOR ANTAGONISTS
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
WO1997017341A1 (en) * 1995-11-08 1997-05-15 Smithkline Beecham Corporation A process of making 3-phenyl-1-methylenedioxyphenyl-indane-2-carboxylic acid derivatives
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
JP2000500444A (ja) * 1995-11-08 2000-01-18 スミスクライン・ビーチャム・コーポレイション ３−フェニル−１−メチレンジオキシフェニル−インダン−２−カルボン酸誘導体の製造プロセス
DE19543639A1 (de) * 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
PT885215E (pt) * 1996-02-13 2006-08-31 Abbott Lab Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina
PT888340E (pt) * 1996-02-13 2002-12-31 Abbott Lab Derivados de acido 4-(benzo-1,3-dioxolil)pirrolidino-3-carboxilico como antagonistas de endotelina
PL328571A1 (en) 1996-02-20 1999-02-01 Bristol Myers Squibb Co Methods of obtaining biphenylisoxazol sulphonamides
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
DE69715865T2 (de) * 1996-07-01 2003-08-07 Schering Corp., Kenilworth Muscarin-antagonisten
AU732213B2 (en) * 1996-08-09 2001-04-12 Merck & Co., Inc. An asymmetric conjugate addition reaction
JPH11514676A (ja) * 1996-08-09 1999-12-14 メルク エンド カンパニー インコーポレーテッド 立体選択的脱酸素化反応
US6172235B1 (en) 1996-08-09 2001-01-09 Merck & Co., Inc. Asymmetric conjugate addition reaction
AU3867997A (en) 1996-08-27 1998-03-19 Shionogi & Co., Ltd. Chromene-3-carboxylate derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
HRP980001A2 (en) * 1997-01-14 1998-10-31 Feng Xu Asymmetric conjugate addition reaction using a chiral additive
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6013674A (en) * 1997-06-02 2000-01-11 Eli Lilly And Company Cell adhesion inhibitors
JP4058507B2 (ja) 1997-07-10 2008-03-12 国立大学法人 東京医科歯科大学 ４，５−ジヒドロ−［１Ｈ］−ベンズ［ｇ］インダゾール−３−カルボン酸誘導体
US6022972A (en) 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
ATE259800T1 (de) * 1998-01-21 2004-03-15 Banyu Pharma Co Ltd Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
HK1039778A1 (zh) 1999-03-19 2002-05-10 Bristol-Myers Squibb Company 制造联苯异恶唑基磺胺的方法
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
PT1180094E (pt) * 1999-05-26 2004-10-29 Warner Lambert Co Aminoacidos policiclicos fundidos como agentes farmaceuticos
US7034055B1 (en) 1999-06-30 2006-04-25 Prescient Neuropharma Inc. 2-aminoindane analogs
EP1244657B1 (en) 1999-12-31 2004-12-29 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
KR100965201B1 (ko) 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 대사 질환의 치료용 화합물
PL1658277T3 (pl) 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
KR100595963B1 (ko) * 2004-04-13 2006-07-05 한국화학연구원 인덴 유도체 및 이의 제조방법
CA2591800A1 (en) 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Tetralin and indane derivatives and uses thereof as 5-ht antagonists
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
ES2552842T3 (es) 2007-02-19 2015-12-02 Marine Polymer Technologies, Inc. Composiciones hemostáticas y regímenes terapéuticos
AU2011239466B2 (en) 2010-04-15 2015-01-22 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -N-acetylglucosamine nanofibers
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CN110343038B (zh) * 2018-04-02 2022-03-15 暨南大学 一种宝乐果单体、提取物及其制备方法和应用
MX2024000313A (es) 2021-07-09 2024-03-06 Plexium Inc Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.
AU2023299045A1 (en) * 2022-06-29 2024-12-19 Amyloid Solution Inc. Novel indenone derivatives and uses thereof
WO2025162194A1 (zh) * 2024-01-31 2025-08-07 上海汇伦医药股份有限公司 钠通道调节剂新化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
US4224341A (en) * 1976-01-12 1980-09-23 Lipha, Lyonnaise Industrielle Pharmaceutique 5-Substituted indan-2 carboxylic acid and functional derivatives
EP0206241A1 (en) * 1985-06-19 1986-12-30 ZAMBON S.p.A. Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
JPS61197557A (ja) * 1985-02-27 1986-09-01 Sankyo Co Ltd インダン誘導体およびその製法
DE3881467T2 (de) * 1987-10-09 1993-10-21 Agency Ind Science Techn Vasokonstriktor-Peptid.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642785A (en) * 1969-08-11 1972-02-15 Merck & Co Inc Indenyl-3-aliphatic amines
US4224341A (en) * 1976-01-12 1980-09-23 Lipha, Lyonnaise Industrielle Pharmaceutique 5-Substituted indan-2 carboxylic acid and functional derivatives
EP0206241A1 (en) * 1985-06-19 1986-12-30 ZAMBON S.p.A. Process for the preparation of cis-5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-indene-3-acetic acid

Also Published As

Publication number Publication date
AU3125993A (en) 1993-06-07
DE69232072T2 (de) 2002-06-20
HUT67665A (en) 1995-04-28
FI942059L (fi) 1994-07-04
FI942059A0 (fi) 1994-05-04
AP9200440A0 (en) 1993-01-31
SK282098B6 (sk) 2001-11-06
FI942059A7 (fi) 1994-07-04
DE69232072D1 (de) 2001-10-25
RO117847B1 (ro) 2002-08-30
CZ287406B6 (cs) 2000-11-15
SK52194A3 (en) 1995-03-08
AU669866B2 (en) 1996-06-27
UA44686C2 (uk) 2002-03-15
TW298590B (pt) 1997-02-21
WO1993008799A1 (en) 1993-05-13
NO941650D0 (no) 1994-05-04
RU2125980C1 (ru) 1999-02-10
SI9200297A (en) 1993-06-30
PL176250B1 (pl) 1999-05-31
CZ110994A3 (en) 1995-01-18
PT101038A (pt) 1994-02-28
NO941650L (no) 1994-07-01
BG98752A (bg) 1995-05-31
MX9206348A (es) 1994-06-30
EP0612244A1 (en) 1994-08-31
MY108579A (en) 1996-10-31
BR9206722A (pt) 1995-07-18
CN1034569C (zh) 1997-04-16
NZ245000A (en) 1996-05-28
CN1145223A (zh) 1997-03-19
EP0612244B1 (en) 2001-09-19
OA09921A (en) 1994-08-15
BG61523B1 (en) 1997-11-28
SI9200297B (sl) 2003-02-28
DK0612244T3 (da) 2002-01-14
CA2122820A1 (en) 1993-05-13
CN1073161A (zh) 1993-06-16
ES2164054T3 (es) 2002-02-16
IL103621A0 (en) 1993-04-04
ATE205711T1 (de) 2001-10-15
PT101038B (pt) 1999-07-30
JP2667294B2 (ja) 1997-10-27
JPH07501322A (ja) 1995-02-09
HK1012251A1 (en) 1999-07-30
KR100342960B1 (pt) 2003-02-11
NO304887B1 (no) 1999-03-01
MA22758A1 (fr) 1993-10-01
EP0612244A4 (en) 1995-05-17
HU9401319D0 (en) 1994-08-29

Similar Documents

Publication Publication Date Title
EP0612244B1 (en) Endothelin receptor antagonists
AP573A (en) Endothelin receptor antagonists.
US6271399B1 (en) Endothelin receptor antagonists
US5817653A (en) Endothelin receptor antagonists
US5716985A (en) Endothelin receptor antagonists
HK1012251B (en) Endothelin receptor antagonists
HK1012252B (en) Endothelin receptor antagonists